Diagnostics R&D


Roche offers an extensive range of diagnostics products and services that support cutting-edge clinical and scientific research. We have R&D facilities in the United States and Europe, augmented by a network of alliances and partnerships that give us broad access to key technologies.





Areas of global research

Given the pharmaceuticals division’s strong oncology portfolio, identifying and validating biomarkers to support the use of Roche’s marketed and developmental cancer medicines is naturally a major focus of research.

Development activities include rare reagents, novel assays, innovative instruments, and information technology such as next generation immunochemistry platforms, protein-chip instruments or tools for molecular diagnostic profiling, and molecular markers.

In our Roche Applied Science sector, priorities include developing new and more powerful DNA microarrays and enhancing the flexibility and efficiency of the ultrafast sequencing technology for the research market. New developments in the fields of automized PCR (Polymerase Chain Reaction) and preparation of nucleic acid samples for PCR analysis are in the pipeline and will offer customers higher throughputs and more seamless integration. The business area has also stepped up to contribute to the global Roche Personalized Healthcare strategy by developing tests with potential diagnostic applications or assay systems that may facilitate drug development, particularly in oncology and inflammatory diseases.

Globally, Roche has approximately 2,000 scientists working in Diagnostics Research centres around the world.

Our R&D sites include:

Branford, US
Burgdorf, Switzerland
Graz, Austria
Indianapolis, US
Madison, US
Mannheim, Germany
Penzberg, Germany
Pleasanton, US
Rotkreuz, Switzerland
Tucson, US

For more information on diagnostics R&D, please click here to visit our global Web site.